AU2013213954B2 - 1H-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors - Google Patents

1H-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors Download PDF

Info

Publication number
AU2013213954B2
AU2013213954B2 AU2013213954A AU2013213954A AU2013213954B2 AU 2013213954 B2 AU2013213954 B2 AU 2013213954B2 AU 2013213954 A AU2013213954 A AU 2013213954A AU 2013213954 A AU2013213954 A AU 2013213954A AU 2013213954 B2 AU2013213954 B2 AU 2013213954B2
Authority
AU
Australia
Prior art keywords
pyrrolo
pyrazole
carboxylic acid
amide
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013213954A
Other languages
English (en)
Other versions
AU2013213954A1 (en
Inventor
Christoper John GRAHAM
Stuart Christopher RAY
Emma Jayne STEFANIAK
Stephen Stokes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vernalis R&D Ltd
Original Assignee
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis R&D Ltd filed Critical Vernalis R&D Ltd
Publication of AU2013213954A1 publication Critical patent/AU2013213954A1/en
Application granted granted Critical
Publication of AU2013213954B2 publication Critical patent/AU2013213954B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2013213954A 2012-01-30 2013-01-30 1H-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors Active AU2013213954B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1201566.5 2012-01-30
GBGB1201566.5A GB201201566D0 (en) 2012-01-30 2012-01-30 New chemical compounds
PCT/GB2013/050212 WO2013114113A1 (en) 2012-01-30 2013-01-30 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors

Publications (2)

Publication Number Publication Date
AU2013213954A1 AU2013213954A1 (en) 2014-08-07
AU2013213954B2 true AU2013213954B2 (en) 2016-02-25

Family

ID=45876325

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013213954A Active AU2013213954B2 (en) 2012-01-30 2013-01-30 1H-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors

Country Status (21)

Country Link
US (3) US10000481B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2809670B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP6199316B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (4) CN107011341A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2013213954B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112014018795B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2862940C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK2809670T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA026657B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2637340T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB201201566D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK1200447A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUE035332T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL233595B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014DN06104A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX352927B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ627361A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL2809670T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT2809670T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013114113A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA201405070B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201201566D0 (en) * 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds
AU2013252514B2 (en) * 2012-04-23 2017-07-20 Genentech, Inc. Intermediates and processes for preparing compounds
CN105705499B (zh) * 2013-08-22 2018-10-12 基因泰克公司 用于制备化合物的方法
CN104829609B (zh) * 2014-02-11 2016-08-03 北大方正集团有限公司 取代的吡啶并嘧啶化合物及其制备方法和应用
MA41559A (fr) * 2015-09-08 2017-12-26 Taiho Pharmaceutical Co Ltd Composé de pyrimidine condensé ou un sel de celui-ci
US10032914B2 (en) * 2015-10-20 2018-07-24 Taiwan Semiconductor Manufacturing Co., Ltd. Semiconductor device and manufacturing method thereof
MX389450B (es) 2016-02-23 2025-03-20 Taiho Pharmaceutical Co Ltd Compuesto novedoso de pirimidina condensada o sal del mismo.
MY201941A (en) 2017-08-21 2024-03-25 Taiho Pharmaceutical Co Ltd Fusion protein of dctn1 protein with ret protein
TW202043198A (zh) 2019-01-17 2020-12-01 美商Ifm Due有限公司 用於治療與sting活性相關之病況的化合物及組合物
CN111518096B (zh) 2019-02-02 2022-02-11 江苏威凯尔医药科技有限公司 两面神激酶jak家族抑制剂及其制备和应用
JP2022542704A (ja) 2019-08-01 2022-10-06 インテグラル バイオサイエンシーズ プライベート リミテッド キナーゼインヒビターとしての複素環式化合物およびその使用
IT202000005527A1 (it) * 2020-03-16 2021-09-16 Univ Degli Studi Di Trento Trattamento terapeutico di cromatinopatie
EP4182030A1 (en) * 2020-07-15 2023-05-24 IFM Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2022015975A1 (en) 2020-07-15 2022-01-20 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
TW202216685A (zh) * 2020-07-15 2022-05-01 美商Ifm Due有限公司 用於治療與sting活性相關的病狀之化合物及組合物
EP4274824A1 (en) 2021-01-08 2023-11-15 IFM Due, Inc. Heterobicyclic compounds having an urea or analogue and their compositions for treating conditions associated with sting activity
CN118613473A (zh) * 2022-01-12 2024-09-06 艾福姆德尤股份有限公司 用于治疗与sting活性相关的病症的化合物和组合物
CN116554170A (zh) * 2023-04-26 2023-08-08 上海大学 4-氟-7-氮杂吲哚的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009089352A1 (en) * 2008-01-08 2009-07-16 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
WO2009140320A1 (en) * 2008-05-13 2009-11-19 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1012976A (en) * 1909-03-25 1911-12-26 Adolf Bordt Adding-machine.
WO2003028724A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
US7531553B2 (en) * 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
NZ590160A (en) * 2003-11-21 2012-07-27 Array Biopharma Inc AKT protein kinase inhibitors
NZ586756A (en) * 2008-01-22 2012-04-27 Vernalis R&D Ltd Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity
MX2010013606A (es) * 2008-06-11 2010-12-21 Genentech Inc Diazacarbazoles y metodos de uso.
KR20120055608A (ko) * 2009-08-06 2012-05-31 메르크 파텐트 게엠베하 신규한 이환 우레아 화합물
WO2011146313A1 (en) * 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
GB201201566D0 (en) * 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009089352A1 (en) * 2008-01-08 2009-07-16 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
WO2009140320A1 (en) * 2008-05-13 2009-11-19 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors

Also Published As

Publication number Publication date
MX352927B (es) 2017-12-14
EP2809670A1 (en) 2014-12-10
US20150011533A1 (en) 2015-01-08
GB201201566D0 (en) 2012-03-14
MX2014009112A (es) 2014-11-10
HUE035332T2 (en) 2018-05-02
CN106866658B (zh) 2021-04-27
EA201491376A1 (ru) 2015-01-30
HK1200447A1 (en) 2015-08-07
CN106866658A (zh) 2017-06-20
BR112014018795B1 (pt) 2020-09-29
AU2013213954A1 (en) 2014-08-07
EA026657B1 (ru) 2017-05-31
IL233595A0 (en) 2014-08-31
CA2862940C (en) 2021-09-14
US20210206762A1 (en) 2021-07-08
CN107011341A (zh) 2017-08-04
CN104203948A (zh) 2014-12-10
PL2809670T3 (pl) 2017-10-31
JP2015505555A (ja) 2015-02-23
BR112014018795A2 (pt) 2017-07-04
US20180362526A1 (en) 2018-12-20
US10000481B2 (en) 2018-06-19
JP6199316B2 (ja) 2017-09-20
PT2809670T (pt) 2017-08-23
CA2862940A1 (en) 2013-08-08
EP2809670B1 (en) 2017-05-17
WO2013114113A1 (en) 2013-08-08
DK2809670T3 (en) 2017-08-28
ES2637340T3 (es) 2017-10-11
IL233595B (en) 2018-05-31
US10889582B2 (en) 2021-01-12
IN2014DN06104A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-08-14
CN111484493A (zh) 2020-08-04
NZ627361A (en) 2016-07-29
ZA201405070B (en) 2016-03-30

Similar Documents

Publication Publication Date Title
AU2013213954B2 (en) 1H-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors
AU2022228150B2 (en) Polycyclic compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
CN106999479B (zh) 可用作sumo活化酶抑制剂的杂芳基化合物
CA2712959C (en) Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity
KR102181915B1 (ko) Trka 키나아제 억제제로서 n-피롤리디닐, n'-피라졸릴-우레아, 티오우레아, 구아니딘 및 시아노구아니딘 화합물
EA019785B1 (ru) Бензофуропиримидиноны в качестве ингибиторов протеинкиназ, фармацевтические композиции, их содержащие, и их применение
CN104211692B (zh) 作为欧若拉激酶抑制剂的衍生物
WO2024097953A1 (en) Naphthyridine compounds for inhibition of raf kinases
HK1240217B (zh) 1h-吡咯并[2,3-b]吡啶衍生物及它们作为激酶抑制剂的用途
HK40025567A (en) 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors
HK1240217A1 (en) 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors
HK1240227A1 (zh) 1h-吡咯并[2,3-b]吡啶衍生物及他们作为激酶抑制剂的用途
WO2011010083A1 (en) Indolyl-pyridone derivatives

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)